Description

OVA-E1 peptide TFA, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes[1].–80°C, 2 years; -20°C, 1 year (Powder, stored under nitrogen, away from moisture)–COVID-19-immunoregulation–C49H77F3N10O16—-[1]Leandro J Carreño, et al. The Half-Life of the T-cell receptor/peptide-major Histocompatibility Complex Interaction Can Modulate T-cell Activation in Response to Bacterial Challenge. Immunology. 2007 Jun;121(2):227-37.–1262750-80-0–1119.19–98.34–O=C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(N)=O)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CCC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)N.OC(C(F)(F)F)=O–Inflammation/Immunology–H2O–JNK;p38 MAPK—-MAPK/ERK Pathway–Peptides